Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sustained annual growth of more than 3.4% in sales of prostate cancer therapies from 2005 to 2015 will be driven primarily by new entries to the market that will add to, rather than replace, existing therapies in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.
According to the new Pharmacor report Prostate Cancer, the success of Sanofi-Aventis's Taxotere (docetaxel) in the treatment of hormone-refractory metastatic prostate cancer has fueled drug developers' interest in novel agents to treat this poor-prognosis population. As a result, drug developers are expected to launch several novel drug classes for prostate cancer treatment including vaccines, vascular endothelial growth factor (VEGF) inhibitors, and vitamin D analogues.
"In addition to a rise in patient share for Taxotere in Europe and Japan over the next 10 years, the entry of novel, high-priced agents, such as Genentech/Roche/Chugai's Avastin (bevacizumab) and the launch of vaccines will expand the market to treat prostate cancer," said Joanne Graham, Ph.D., analyst at Decision Resources, Inc. "Novel agents with proven benefit have huge potential and could add an impressive $1.5 billion in annual sales to this underserved market."
About Prostate Cancer
Prostate cancer is a disease of enormous significance to public health. Among men in developed countries, it is one of the leading malignancies in terms of share of incident cancer cases, which is increasing in line with general population aging. The high incidence of prostate cancer makes it the second-leading cancer cause of death in men in the United States.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.decisionresources.com/